Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONCT-534 in Metastatic Castration-Resistant Prostate Cancer
NCT05917470Phase 2Terminated
- Sponsor
- Oncternal Therapeutics
- Start
- Sep 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of ONCT-534 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Oncternal Therapeutics. Primary endpoint: Dose Limiting Toxicities at Day 28. Started Sep 2023; status: terminated.
02
Drugs
ONCT-534
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05917470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05917470.